Recombinant human EIF3I (325aa) fused with T7 Tag at N-terminal was expressed in E. coli.
1.0 mg/ml, sterile-filtered, in 20 mM pH 8.0 Tris-HCl Buffer, with proprietary formulation of NaCl, KCl, EDTA, Sucrose and DTT.
MASMTGGQQMGRGEFMKPILLQGHERSITQIKYNREGDLLFTVAKDPIVNVWYSVNGERLGTYMGHTGAVWCVDA DWDTKHVLTGSADNSCRLWDCETGKQLALLKTNSAVRTCGFDFGGNIIMFSTDKQMGYQCFVSFFDLRDPSQIDN NEPYMKIPCNDSKITSAVWGPLGECIIAGHESGELNQYSAKSGEVLVNVKEHSRQINDIQLSRDMTMFVTASKDN TAKLFDSTTLEHQKTFRTERPVNSAALSPNYDHVVLGGGQEAMDVTTTSTRIGKFEARFFHLAFEEEFGRVKGHF GPINSVAFHPDGKSYSSGGEDGYVRIHYFDPQYFEFEFEA
>90% by SDS-PAGE.
1. May be used for in vitro TGFb1 mediated EMT regulation study with intracellular delivery of this protein.2. As soluble / native protein, may be used as enzymatic substrate protein for kinase and ubiquitin assay development.3. May be used for mapping EIF3I protein-protein interaction.4. May be used as antigen for specific antibody development.
Keep at -80°C for long term storage. Product is stable at 4 °C for at least 7 days.